bioMérieux Shares Dip 1.13% at Close Due to Technical Resistance

Technical Analysis of the Day's Trading

bioMérieux's stock ended the trading session on Wednesday, January 7th at 113.50 euros, down by 1.13% compared to the previous day. The in vitro diagnostics specialist's shares moved in limited volumes, with only 0.17% of the capital traded, indicating investor caution. The stock encountered resistance at its technical threshold of 114.80 euros and failed to break through this level despite recent upward trends. Over the past seven days, bioMérieux has still managed a gain of 3.09%, driven by momentum that began in late December. This consolidation occurs in a context where the stock remains under medium-term pressure. With a 200-day moving average at 115.62 euros, the price remains below this long-term benchmark, indicating a still fragile trajectory. Conversely, a clear crossing of the 50-day (108.53 euros) and 20-day (108.45 euros) moving averages confirms the technical recovery that began in recent weeks.

Market Indicators and Fundamental Analysis

The RSI, set at 81, places the stock in a distinctly overbought zone, reflecting rapid accumulation that could justify a technical pause or a corrective movement. This indicator suggests that recent buyers have taken significant positions, which may temporarily limit immediate upward potential. Meanwhile, the MACD remains positive with a line at 1.33 and a signal at 0.77, confirming that there is still active bullish momentum, although the dynamic could lose steam. On the fundamental side, bioMérieux revised its 2025 growth forecasts downward last November following a disappointing third quarter, but Invest Securities upgraded its recommendation to 'buy' with a target price of 124 euros on November 10th, representing a potential upside of 9.3% from the current price. The company continues to face headwinds, particularly in China and in the respiratory segment, but analysts are banking on the execution of the strategic plan to support profitability.